Segall Bryant & Hamill LLC Buys 27,128 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Segall Bryant & Hamill LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 51.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 79,518 shares of the biopharmaceutical company's stock after purchasing an additional 27,128 shares during the period. Segall Bryant & Hamill LLC owned 0.05% of TG Therapeutics worth $2,393,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. State Street Corp lifted its holdings in TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after buying an additional 2,398,015 shares during the period. Principal Financial Group Inc. boosted its holdings in TG Therapeutics by 1,549.4% in the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after acquiring an additional 725,371 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in TG Therapeutics during the 4th quarter valued at approximately $14,508,000. Braun Stacey Associates Inc. bought a new position in TG Therapeutics during the 4th quarter worth approximately $13,328,000. Finally, Castellan Group acquired a new position in shares of TG Therapeutics in the 4th quarter worth approximately $8,539,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Down 4.3 %

NASDAQ TGTX traded down $1.68 on Tuesday, hitting $37.75. 1,939,724 shares of the company were exchanged, compared to its average volume of 3,071,135. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market cap of $5.93 billion, a PE ratio of -377.46 and a beta of 2.30. The stock has a fifty day moving average of $34.73 and a 200-day moving average of $30.60.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. As a group, analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.50% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on TGTX. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.